In the early 2000s, the company Lundbeck signed agreements with four companies which, as a result, undertook not to market generic drugs based on citalopram in Europe. Lundbeck had previously threatened them with legal action for patent infringement. The agreement included large compensatory payments by Lundbeck to the generic drug manufacturers (1).
展开▼
